Altria Group Stock Earnings Reports

Altria reported a solid start to 2026 with adjusted diluted EPS up 7.3% in Q1. Key financials and operational highlights: smokeable products delivered strong income growth with PM USA executing a total-portfolio strategy; adjusted OCI margins in smokeables expanded (smokeable adjusted OCI up 6.3%; margin 65.1%). Domestic cigarette volumes showed moderation in decline (reported down 2.4%; estimated shipment down ~4% after trade), with premium Marlboro holding strength in the premium segment and Basic gaining in the discount segment. Oral tobacco: Helix/on! shipment volume rose ~18% (over 46 million cans shipped) and on! PLUS was rolled out nationally (available in ~100,000 stores, ~85% of nicotine pouch category volume) and is the only product authorized under the FDA pilot program to date. The company emphasized responsible marketing and wholesale/retail execution to support on! PLUS. E-vapor: management sees early signs the prior rapid growth driven by illicit flavored disposables is moderating due to enforcement and supply disruption, but the market remains dominated by illicit disposables (~70% of volume); Altria calls for a more efficient, predictable FDA authorization pathway combined with sustained enforcement to restore a compliant marketplace. Capital allocation and balance sheet: paid ~$1.8 billion in dividends and repurchased 4.5 million shares for $280 million in Q1 (remaining repurchase capacity ~$72 million); debt-to-EBITDA ~1.9x after retiring ~$1B matured debt. Guidance: Altria reaffirmed full-year 2026 adjusted diluted EPS guidance of $5.56–$5.72 (growth of 2.5%–5.5% vs. $5.42 in 2025) and now expects EPS growth to be more balanced between H1 and H2. Corporate: CEO Billy Gifford announced this will be his final earnings call and reiterated confidence in the leadership and strategy going forward. Management flagged macro uncertainty (consumer pressure, gas prices) as a risk that could affect category dynamics.